Altruist Biologics' Suzhou Site Receives EMA GMP Certification, Enabling Product Commercialization for the European Market

Altruist Biologics said its Suzhou commercial manufacturing facility has passed a European Medicines Agency (EMA) Good Manufacturing Practice (GMP) inspection with zero critical findings, the company’s first successful EMA GMP certification for the site. The inspection supported an EU marketing authorization application for a biologics product from a top biopharmaceutical client. Altruist states the EMA evaluated the full biologics manufacturing lifecycle, including quality systems and operational performance, and recognized the facility’s quality management system, infrastructure, technical capabilities, data integrity controls, and organizational management. The company also cites a Quality Risk Management framework for improving compliance risk identification and technology-transfer predictability. Suzhou offers 60,000 liters of antibody manufacturing capacity plus an ADC clinical manufacturing line.